drugset / Trial / NCT03155100
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines
Phase 2
Completed
15 enrolled
Raija Silvennoinen
Amgen · collabBristol-Myers Squibb · collabHospital District of Helsinki and Uusimaa · collab
NaSingle-groupOpen-labelTreatment
Summary
The main aim of this study is to assess the ORR with a new drug combination, carfilzomib (CAR) + elotuzumab (ELO) + dexamethasone (CAR-ELO-Dex).
Timeline
- Start
- 2017-08-07
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 70 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Elotuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |